| Primary |
| Benign Prostatic Hyperplasia |
42.9% |
| Glaucoma |
42.9% |
| Lymphoma |
7.1% |
| Type 2 Diabetes Mellitus |
7.1% |
|
| Ocular Hypertension |
37.5% |
| Azoospermia |
12.5% |
| Erectile Dysfunction |
12.5% |
| Loss Of Consciousness |
12.5% |
| Penile Oedema |
12.5% |
| Vomiting |
12.5% |
|
| Secondary |
| Product Used For Unknown Indication |
66.7% |
| Benign Prostatic Hyperplasia |
14.3% |
| Drug Use For Unknown Indication |
9.5% |
| Bladder Spasm |
4.8% |
| Plasma Cell Myeloma |
4.8% |
|
| Constipation |
10.0% |
| Hypotension |
10.0% |
| Muscle Atrophy |
10.0% |
| Pneumonia Aspiration |
10.0% |
| Swelling |
10.0% |
| Syncope |
10.0% |
| Testicular Mass |
10.0% |
| Tremor |
10.0% |
| Urinary Retention |
10.0% |
| Vascular Pseudoaneurysm |
10.0% |
|
| Concomitant |
| Drug Use For Unknown Indication |
26.7% |
| Product Used For Unknown Indication |
16.3% |
| Hypertension |
12.4% |
| Benign Prostatic Hyperplasia |
7.7% |
| Diabetes Mellitus |
4.0% |
| Prophylaxis |
3.5% |
| Prostate Cancer |
3.5% |
| Colorectal Cancer |
2.9% |
| Rheumatoid Arthritis |
2.7% |
| Diffuse Large B-cell Lymphoma |
2.6% |
| Hiv Infection |
2.4% |
| Non-small Cell Lung Cancer |
2.4% |
| Atrial Fibrillation |
2.0% |
| Pain |
1.8% |
| Renal Cell Carcinoma |
1.8% |
| Multiple Myeloma |
1.6% |
| Thrombosis Prophylaxis |
1.6% |
| Chronic Obstructive Pulmonary Disease |
1.3% |
| Colon Cancer |
1.3% |
| Depression |
1.3% |
|
| Pneumonia |
9.8% |
| Pulmonary Embolism |
7.1% |
| Syncope |
7.1% |
| Renal Failure Acute |
6.3% |
| Nausea |
5.4% |
| Peripheral Motor Neuropathy |
5.4% |
| Sepsis |
5.4% |
| Septic Shock |
5.4% |
| Gastrointestinal Haemorrhage |
4.5% |
| Rectal Haemorrhage |
4.5% |
| Renal Failure |
4.5% |
| Urticaria |
4.5% |
| Weight Decreased |
4.5% |
| Weight Increased |
4.5% |
| Acute Myocardial Infarction |
3.6% |
| Diabetes Mellitus |
3.6% |
| Pancreatitis |
3.6% |
| Polyneuropathy |
3.6% |
| Sopor |
3.6% |
| Transient Ischaemic Attack |
3.6% |
|
| Interacting |
| Product Used For Unknown Indication |
90.0% |
| Drug Use For Unknown Indication |
10.0% |
|
| Urinary Retention |
80.0% |
| Drug Interaction |
20.0% |
|
